Lyophilization is not inherently inefficient. It is operated with inefficiency because the actual product condition inside the vial is typically not measured directly.

Lyophilization is not inherently inefficient. It is operated that way.
In pharmaceutical freeze-drying, heat is transferred indirectly from thermally controlled shelves through the vial into the product. Shelf systems may be precisely controlled, but the actual product condition inside the vial remains only partially visible. This creates a process that is heterogeneous by nature rather than truly uniform across the batch.

Vials do not dry uniformly. Heat transfer varies across positions. Edge, corner, and center vials behave differently. Product temperature and drying progression are therefore not identical across the load.
Because this uncertainty cannot be resolved with shelf temperature alone, many processes are run with substantial safety margins. In practice, these margins can easily reach around 30% in cycle time to avoid local overheating, collapse risk, or incomplete drying. The result is avoidable over-drying, longer primary drying, and underused equipment capacity.

This is not only a technical issue. It is a manufacturing and supply issue.
When the product itself is not directly understood, the consequences are immediate: higher cost of goods, longer batch times, reduced annual throughput, delayed transfer decisions, and avoidable pressure on drug availability. A process operated with excess time is a process that sacrifices capacity every single cycle.

To address these limitations, the industry has invested in alternative equipment concepts and surrounding process upgrades: microwave-assisted approaches, spray drying, stronger refrigeration concepts, automation, robotics, surrogate signals, and advanced modeling.
These efforts may improve individual parts of the system. But they often do not solve the root problem: the product remains insufficiently visible during the run.

Shelf temperature is not product temperature.
As long as the real product temperature inside the vial is unknown, process understanding remains incomplete. Without direct product data, critical process interpretation still depends on assumptions, indirect signals, and conservative operating windows. That is why optimization often remains slower than expected despite major investment in equipment and infrastructure.

The impact becomes especially visible during development, scale-up, and tech transfer. Engineering programs may require up to six runs before a robust process is achieved. Each additional run can mean roughly three to four months of added time when planning, execution, analytics, review, and parameter adjustment are included.
This turns process uncertainty into a serious timeline penalty. Repeated runs consume development resources, delay process readiness, and compress the commercially valuable time window of the product.

Tempris closes the measurement gap by making real product temperature inside the vial directly visible. Instead of inferring product behavior from machine-side conditions, Tempris provides direct insight into what the product actually experiences during primary drying.
This allows teams to identify hot and cold spots, understand batch heterogeneity, and evaluate process performance based on actual product conditions rather than assumptions alone.

LyoCLC® converts this product data into process intelligence.
Using measured temperature data from real runs, LyoCLC® supports backward calculation of Kv and Rp, data-based evaluation of engineering runs, and targeted adaptation of process parameters. This changes the development logic from repeated trial-and-error toward informed optimization after only a limited number of runs.
The practical value is clear: fewer engineering iterations, faster scale-up and transfer, reduced safety margins, shorter cycle times, and more efficient manufacturing.

• Safety margins can be around 30% because uncertainty is compensated with time and conservative settings.
• Engineering programs can require up to 6 runs before a robust process window is reached.
• Each additional engineering run can add roughly 3–4 months when execution, analytics, and decision cycles are included.
• The core reason is not lack of machine control alone, but lack of direct product-level visibility inside the vial.